Who to call at Keros Therapeutics, Inc., and when
Fundz watches for the moments Keros Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Keros Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Keros Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Keros Therapeutics, Inc.. With Fundz connected, it knows.
Keros Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
kerostx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Keros Therapeutics agreed to repurchase 10,176,595 shares from ADAR1 and Pontifax at $17.75 per share, for about $181 million, and two directors resigned from the board. The block, roughly 25% of outstanding common stock, is being retired and the board is being reshaped, which matters for governance and capital allocation.
Key Takeaways
Keros will buy back 10,176,595 shares (about 25% of outstanding common stock as of October 14, 2025) from the ADAR1 and Pontifax parties at $17.75 per share, for an aggregate price of roughly $181 mil
Tomer Kariv and Ran Nussbaum resigned from the board and all committees, as required under the Pontifax Repurchase Agreement, and the repurchase is expected to close on or about October 15, 2025.
3 more takeaways
Related Filings (14)
14 more filings from Keros Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Keros Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.